Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01237041 · ClinicalTrials.gov registry record · Phase 1
Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children
A Phase 1 study, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- Terminated
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT01237041 is a Phase 1 study that was terminated before completion, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 37 participants.
The verdict
NCT01237041, a Phase 1 study, was terminated before completion, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
Background: \- Overweight and obese children and adults often have lower levels of growth hormone in the blood. Regulation of growth hormone may be tied to weight and free fatty acids in the blood. Current tests of growth hormone (such as those used when evaluating the heights of children who are markedly shorter than other children of comparable age) may be affected by other factors, including obesity. Researchers are interested in evaluating the levels of growth hormone and free fatty acids in the blood of children between 7 and 14 years of age who weigh more than children of a comparable age, or who are shorter than other children of a comparable age and have been recommended for growth hormone testing as part of an evaluation for their height. Objectives: \- To determine the effect of changes in free fatty acids in the blood on changes in growth hormone secretion in overweight or shorter children and young adolescents. Eligibility: \- Children and adolescents between 7 and 14 years of age who weigh more than or are shorter than other children of a comparable age and do not have any medical illnesses. Design: * Participants will have two study visits, one of which will be a half day screening visit in the outpatient clinic and one of which will require 2 nights as an inpatient at the National Institutes of Health Clinical Center. * Participants should not eat or drink anything except water after 10 PM the night before or on the morning of the screening visit. * At the screening visit, participants will have a physical examination and medical history, provide blood and urine samples, have an oral glucose tolerance test (to check blood sugar levels), and have an x-ray of the left hand to check bone age. * The inpatient study visit will involve a physical examination and medical history, a full x-ray scan to study body fat and muscle, frequent blood tests throughout the visit, and various medications to stimulate growth hormone production and lower levels of
Interventions
- DRUG Placebo First
- DRUG Niacin First
- DRUG Dose-Establishing Study 1 Niacin 250mg
- DRUG Dose-Establishing Study 1 Niacin 500mg
- DRUG Dose-Establishing Study 2 Niacin 500mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2011-07-01 |
| Est. Completion | 2017-12-13 |
| Phase | Phase 1 |
Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)305 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01237041
The ClinicalTrials.gov registry entry for NCT01237041 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo First is the first listed.
NCT01237041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01237041 about?
NCT01237041 is a clinical study titled "Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children". Background: \- Overweight and obese children and adults often have lower levels of growth hormone in the blood. Regulation of growth hormone may be tied to weight and free fatty acids in the blood. Current tests of growth hormone (such as those used when evaluating the heights of children who are m...
What is the current status of trial NCT01237041?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2011-07-01. Estimated completion is 2017-12-13.
What interventions are being tested in trial NCT01237041?
The interventions under investigation include: Placebo First (DRUG), Niacin First (DRUG), Dose-Establishing Study 1 Niacin 250mg (DRUG), Dose-Establishing Study 1 Niacin 500mg (DRUG), Dose-Establishing Study 2 Niacin 500mg (DRUG).
Who is sponsoring clinical trial NCT01237041?
This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.